Literature DB >> 20428981

Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma.

Keiko Onda1, Kazutoshi Iijima, Yohko U Katagiri, Hajime Okita, Masahiro Saito, Toshiaki Shimizu, Nobutaka Kiyokawa.   

Abstract

B cell-activating factor belonging to the tumor necrosis factor superfamily (BAFF) is a crucial factor for B cell development and is involved in the survival of malignant B cells, but its effect on B cell precursors (BCPs) remains unclear. We investigated BCP acute lymphoblastic leukemia (-ALL) cells for BAFF receptor (-R) expression and compared the effect of BAFF on BCP-ALL cells and Burkitt lymphoma (BL) cells. Expression of BAFF-R was detected in some cell lines and some clinical specimens of both BL and BCP-ALL. BAFF acted on both BL and BCP-ALL cells and promoted proliferation by both. BAFF also inhibited apoptosis by BL cells induced by cross-linking of cell surface molecules and anticancer drugs, but failed to inhibit apoptosis by BCP-ALL cells. BAFF induced prompt and obvious activation of the NF-kappaB signaling pathway in BL cells, but only weak and delayed activation of the pathway in BCP-ALL cells. The results of this study indicate that some BCP-ALL cells and some BL cells express BAFF-R, but that the effects of BAFF on BCP-ALL cells are different from its effects on mature B cell malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428981     DOI: 10.1007/s12185-010-0567-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  41 in total

1.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

Review 2.  Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.

Authors:  Stéphanie Haiat; Christian Billard; Claire Quiney; Florence Ajchenbaum-Cymbalista; Jean-Pierre Kolb
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

3.  TALL-1 is a novel member of the TNF family that is down-regulated by mitogens.

Authors:  H B Shu; W H Hu; H Johnson
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

4.  Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase.

Authors:  A Mukhopadhyay; J Ni; Y Zhai; G L Yu; B B Aggarwal
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

5.  Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

Authors:  Anne J Novak; Jaime R Darce; Bonnie K Arendt; Brandon Harder; Kathy Henderson; Wayne Kindsvogel; Jane A Gross; Philip R Greipp; Diane F Jelinek
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

6.  Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function.

Authors:  Kalpit A Vora; Li Chun Wang; Sambasiva P Rao; Zhong-Ying Liu; Gerard R Majeau; Anne H Cutler; Paula S Hochman; Martin L Scott; Susan L Kalled
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

7.  Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.

Authors:  Bing He; Amy Chadburn; Erin Jou; Elaine J Schattner; Daniel M Knowles; Andrea Cerutti
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

8.  Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.

Authors:  Seok Jin Kim; Seung Jin Lee; In Young Choi; Yong Park; Chul Won Choi; In Sun Kim; Woosung Yu; Hee Sang Hwang; Byung Soo Kim
Journal:  Eur J Haematol       Date:  2008-05-27       Impact factor: 2.997

9.  TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation.

Authors:  X Z Xia; J Treanor; G Senaldi; S D Khare; T Boone; M Kelley; L E Theill; A Colombero; I Solovyev; F Lee; S McCabe; R Elliott; K Miner; N Hawkins; J Guo; M Stolina; G Yu; J Wang; J Delaney; S Y Meng; W J Boyle; H Hsu
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

10.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  8 in total

1.  Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.

Authors:  Reshmi Parameswaran; Min Lim; Fei Fei; Hisham Abdel-Azim; Anna Arutyunyan; Isabelle Schiffer; Margaret E McLaughlin; Hermann Gram; Heather Huet; John Groffen; Nora Heisterkamp
Journal:  Mol Cancer Ther       Date:  2014-05-13       Impact factor: 6.261

2.  Prokaryotic expression, purification and functional characterization of recombinant human RIP2.

Authors:  Xin Cai; Min Wang; Haibo Kong; Jing Liu; Ye Liu; Wengrong Xia; Minji Zou; Jiaxi Wang; Hang Su; Donggang Xu
Journal:  Mol Biol Rep       Date:  2012-11-08       Impact factor: 2.316

3.  Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.

Authors:  Troy A Luster; Ipsita Mukherjee; Jeffrey A Carrell; Yun Hee Cho; Jeffrey Gill; Lizbeth Kelly; Andy Garcia; Christopher Ward; Luke Oh; Stephen J Ullrich; Thi-Sau Migone; Robin Humphreys
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

4.  Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.

Authors:  L Zhang; Y Jiang; Y Zheng; Y Zeng; Z Yang; G Huang; D Liu; M Gao; X Shen; G Wu; X Yan; F He
Journal:  Leukemia       Date:  2010-11-19       Impact factor: 11.528

5.  Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.

Authors:  R Parameswaran; M Yu; M-A Lyu; M Lim; M G Rosenblum; J Groffen; N Heisterkamp
Journal:  Leukemia       Date:  2012-02-29       Impact factor: 11.528

Review 6.  Molecular signature in HCV-positive lymphomas.

Authors:  Valli De Re; Laura Caggiari; Marica Garziera; Mariangela De Zorzi; Ombretta Repetto
Journal:  Clin Dev Immunol       Date:  2012-08-16

Review 7.  B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia.

Authors:  Michal Rihacek; Julie Bienertova-Vasku; Dalibor Valik; Jaroslav Sterba; Katerina Pilatova; Lenka Zdrazilova-Dubska
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

8.  A Novel STK4 Mutation Impairs T Cell Immunity Through Dysregulation of Cytokine-Induced Adhesion and Chemotaxis Genes.

Authors:  Andrea Guennoun; Salim Bougarn; Taushif Khan; Rafah Mackeh; Mahbuba Rahman; Fatima Al-Ali; Manar Ata; Waleed Aamer; Debra Prosser; Tanwir Habib; Evonne Chin-Smith; Khawla Al-Darwish; Qian Zhang; Alya Al-Shakaki; Amal Robay; Ronald G Crystal; Khalid Fakhro; Amal Al-Naimi; Eman Al Maslamani; Amjad Tuffaha; Ibrahim Janahi; Mohammad Janahi; Donald R Love; Mohammed Yousuf Karim; Bernice Lo; Amel Hassan; Mehdi Adeli; Nico Marr
Journal:  J Clin Immunol       Date:  2021-08-24       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.